Evidence map›Paper›PMID 25741163›Full record

SynthesisWorld journal of gastroenterology2015

Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?

Zhi-Fa Lv, Fu-Cai Wang, Hui-Lie Zheng, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv

3 registry-linked trialsOpen access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05431075 phase4completednot on this mapstarted 2022, after this paper: background citation

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.

TypeinterventionalSponsorShandong UniversityRan2022 to 2024Enrolled406ConditionsHelicobacter Pylori InfectionArmsAmoxicillin, Tetracycline tid, Tetracycline qid, Bismuth Potassium Citrate, Colloidal Bismuth Pectin
NCT05432115 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.

TypeinterventionalSponsorShandong UniversityRan2022 to 2023Enrolled407ConditionsHelicobacter Pylori InfectionArmsTetracyclin
NCT05802888 phase4unknown statusnot on this mapstarted 2023, after this paper: background citation

Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.

TypeinterventionalSponsorShandong UniversityRan2023 to 2024Enrolled260ConditionsHelicobacter Pylori InfectionArmsTetracycline 500mg tid, Tetracycline 500mg qid
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Rescue therapy for refractoryTherapeutic advances in gastroenterology · 2023
    Review
  6. Article
  7. Review
  8. Current guidelines forWorld journal of clinical cases · 2022
    Review
  9. Article
  10. Review
  11. Progresses about the Interplay among Clarithromycin, Immune and Central Nervous Systems.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhi-Fa LvZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Fu-Cai WangZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Hui-Lie ZhengZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Ben WangZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Yong XieZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Xiao-Jiang ZhouZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Nong-Hua LvZhi-Fa Lv, Fu-Cai Wang, Ben Wang, Yong Xie, Xiao-Jiang Zhou, Nong-Hua Lv, Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
Nanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo access the efficacy of combination with amoxicillin and tetracycline for eradication of Helicobacter pylori (H. pylori), thus providing clinical practice guidelines.

methodsPubMed, EMBASE, Cochrane Central Register of Controlled Trials, Science Citation Index, China National Knowledge Infrastructure, Wanfang, and Chinese Biomedical Literature databases and abstract books of major European, American, and Asian gastroenterological meetings were searched. All clinical trials that examined the efficacy of H. pylori eradication therapies and included both tetracycline and amoxicillin in one study arm were selected for this systematic review and meta-analysis. Statistical analysis was performed with Comprehensive Meta-Analysis Software (Version 2). Subgroup, meta-regression, and sensitivity analyses were also carried out.

resultsThirty-three studies met the inclusion criteria. The pooled odds ratio (OR) was 0.90 (95%CI: 0.42-1.78) for quadruple therapy with amoxicillin and tetracycline vs other quadruple regimens, and total eradication rates were 78.1% by intention-to-treat (ITT) and 84.5% by per-protocol (PP) analyses in the experimental groups. The pooled eradication rates of 14-d quadruple regimens with a combination of amoxicillin and tetracycline were 82.3% by ITT and 89.0% by PP, and those of 10-d regimens were 84.6% by ITT and 93.7% by PP. The OR by ITT were 1.21 (95%CI: 0.64-2.28) for triple regimens with amoxicillin and tetracycline vs other regimens and 1.81 (95%CI: 1.37-2.41) for sequential treatment with amoxicillin and tetracycline vs other regimens, respectively.

conclusionThe effectiveness of regimens employing amoxicillin and tetracycline for H. pylori eradication may be not inferior to other regimens, but further study should be necessary.

Indexed as

AmoxicillinAnti-Bacterial AgentsDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansOdds RatioRemission InductionRisk FactorsTetracyclineTreatment OutcomeAmoxicillinAnti-Bacterial AgentsTetracyclineAmoxicillinHelicobacter pyloriMeta-analysisSystemic reviewTetracycline

Identifiers

PMID25741163
PMCPMC4342932
OpenAlexW2030839760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.